Krzysztof Kus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6624845/publications.pdf

Version: 2024-02-01



#	Article	lF	CITATIONS
1	Patients' awareness of the prevention and treatment of the selected podiatry diseases. Journal of Cosmetic Dermatology, 2022, 21, 2889-2896.	1.6	3
2	Impact of bariatric surgery on depression, anxiety and stress symptoms among patients with morbid obesity: international multicentre study in Poland and Germany. BJPsych Open, 2022, 8, e32.	0.7	4
3	Assessment of the Impact of the COVID-19 Pandemic on the Pro-Health Behavior of Poles. International Journal of Environmental Research and Public Health, 2022, 19, 1299.	2.6	5
4	Social Attitude to COVID-19 and Influenza Vaccinations after the Influenza Vaccination Season and between the Second and Third COVID-19 Wave in Poland, Lithuania, and Ukraine. International Journal of Environmental Research and Public Health, 2022, 19, 2042.	2.6	9
5	The Impact of Health Policy on Patients' Awareness of the Risks Associated with Obesity: An International Multicenter Study in Poland and Germany. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 723-732.	2.4	0
6	Neurologists' Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients—Comparative Analysis from Poland and Egypt. International Journal of Environmental Research and Public Health, 2022, 19, 4169.	2.6	1
7	Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland. Vaccines, 2022, 10, 434.	4.4	12
8	Medical university students' perspective on marketing of dietary supplements. Acta Poloniae Pharmaceutica, 2021, 78, 205-218.	0.1	1
9	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 3243-3252.	2.4	3
10	The comparison of Kardia Mobile and Hartmann Veroval 2 in 1 in detecting first diagnosed atrial fibrillation. Cardiology Journal, 2021, , .	1.2	1
11	Costs of Stroke and Incidence of First Diagnosis of Atrial Fibrillation at Time of Stroke. Neurology Ward Hospital Poznań, Poland 2018. Healthcare (Switzerland), 2021, 9, 999.	2.0	2
12	A survey of pharmacists' knowledge, attitudes and barriers in pharmaceutical care concept in Poland. BMC Medical Education, 2021, 21, 458.	2.4	11
13	Analysis of pharmacotherapy regimen and costs in patients with drug-resistant epilepsy following vagus nerve stimulation therapy: a single-center study (Poland). Acta Neurologica Belgica, 2020, 120, 115-122.	1.1	2
14	Effect of Different Blood-Pressure-Lowering Regimens on the Blood Pressure Control among Hypertensive Patients Treated in Hospital Conditions. International Journal of Hypertension, 2020, 2020, 1-8.	1.3	0
15	Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences. Scientia Pharmaceutica, 2020, 88, 7.	2.0	2
16	Non-pharmacological treatments of inpatients with major depression – The case of Polish (Poznan) and German (Kiel) hospital. Complementary Therapies in Clinical Practice, 2020, 39, 101129.	1.7	5
17	Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions. Pharmacology Biochemistry and Behavior, 2020, 189, 172855.	2.9	1
18	Drug shortages as a result of parallel export in Poland – Pharmacists' opinions. Health Policy, 2020, 124, 563-567.	3.0	7

Krzysztof Kus

#	Article	IF	CITATIONS
19	How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. Postepy Dermatologii I Alergologii, 2020, 37, 986-994.	0.9	2
20	Antistress and antidepressant properties of dapoxetine and vortioxetine. Acta Neurobiologiae Experimentalis, 2020, 80, 217-224.	0.7	0
21	Costs of inpatient care of depression in 2014 in Polish (Poznan) and German (Kiel) hospital. International Journal of Psychiatry in Clinical Practice, 2019, 23, 258-264.	2.4	5
22	Safety of medicines—Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Pharmacoepidemiology and Drug Safety, 2019, 28, 1543-1551.	1.9	15
23	Antidepressant and anxiolytic efficacy of single, chronic and concomitant use of vortioxetine, dapoxetine and fluoxetine in prenatally stressed rats. Acta Neurobiologiae Experimentalis, 2019, 79, 13-24.	0.7	7
24	Access to vaccination in the Greater Poland (Poland). Acta Poloniae Pharmaceutica, 2019, 76, 195-201.	0.1	3
25	ANALYSIS OF CHRONIC MYELOID LEUKEMIA PHARMACOTHERAPY COSTS IN POLAND. Acta Poloniae Pharmaceutica, 2019, 76, 175-183.	0.1	0
26	THE PRESCRIPTION TO OVER-THE-COUNTER SWITCHES AND DOUBLE REGISTRATION OF MEDICINES - THE PERSPECTIVE OF PHARMACISTS FROM THE GREATER POLAND Acta Poloniae Pharmaceutica, 2019, 76, 907-912.	0.1	0
27	The influence of olanzapine and aripiprazole on spatial memory of female rats exposed to stress in the perinatal period. Acta Poloniae Pharmaceutica, 2019, 76, 885-893.	0.1	0
28	Antidepressant and anxiolytic efficacy of single, chronic and concomitant use of vortioxetine, dapoxetine and fluoxetine in prenatally stressed rats. Acta Neurobiologiae Experimentalis, 2019, 79, 13-24.	0.7	2
29	The economic burden of inpatient care of depression in Poznan (Poland) and Kiel (Germany) in 2016. PLoS ONE, 2018, 13, e0198890.	2.5	5
30	Affordability of medicines in the European Union. PLoS ONE, 2017, 12, e0172753.	2.5	27
31	Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol. Acta Neurobiologiae Experimentalis, 2017, 77, 86-93.	0.7	2
32	Misuse of OTC drugs in Poland. Health Policy, 2016, 120, 875-881.	3.0	21
33	The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel. Psychiatric Quarterly, 2016, 87, 595-603.	2.1	6
34	Coadministration of tramadol with aripiprazole and venlafaxine—The effect on spatial memory functions in male rats. Pharmacological Reports, 2016, 68, 451-456.	3.3	7
35	The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol. Pharmacological Reports, 2016, 68, 415-422.	3.3	5
36	The Cost of Inpatient Care of Schizophrenia in the Polish and Ukrainian Academic Centers—Poznan and Lviv. Academic Psychiatry, 2015, 39, 165-173.	0.9	9

Krzysztof Kus

#	Article	IF	CITATIONS
37	Schizophrenia and Employment: Evaluation From Professionals Point of View. Psychiatric Quarterly, 2015, 86, 569-579.	2.1	16
38	Biochemical and cognitive impairments observed in animal models of schizophrenia induced by prenatal stress paradigm or methylazoxymethanol acetate administration. Acta Neurobiologiae Experimentalis, 2015, 75, 314-25.	0.7	17
39	Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats. Acta Neuropsychiatrica, 2014, 26, 112-119.	2.1	7
40	Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats. Drug and Chemical Toxicology, 2014, 37, 281-289.	2.3	5
41	The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats. Pharmacological Reports, 2014, 66, 404-411.	3.3	26
42	Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period. Pharmacological Reports, 2013, 65, 30-43.	3.3	17
43	Concomitant use of tramadol and venlafaxine – evaluation of antidepressant-like activity and other behavioral effects in rats. Pharmacological Reports, 2012, 64, 1350-1358.	3.3	37
44	Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats. Pharmacological Reports, 2011, 63, 372-380.	3.3	10
45	Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacological Reports, 2011, 63, 898-907.	3.3	55
46	Effect of lamotrigine and environmental enrichment on spatial memory and other behavioral functions in rats. Arzneimittelforschung, 2010, 60, 307-314.	0.4	4
47	Effect of valproic acid and environmental enrichment on behavioral functions in rats. Arzneimittelforschung, 2010, 60, 471-478.	0.4	6
48	Memory Improving and Antidepressant Effects of Topiramate in Rats. Arzneimittelforschung, 2009, 59, 487-492.	0.4	5
49	Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacological Reports, 2009, 61, 1017-1023.	3.3	63
50	The influence of tobacco smoke and nicotine on antidepressant and memory-improving effects of venlafaxine. Human and Experimental Toxicology, 2006, 25, 199-209.	2.2	27
51	Antidepressant and Memory Affecting Influence of Estrogen and Venlafaxine in Ovariectomized Rats. Arzneimittelforschung, 2005, 55, 153-159.	0.4	15
52	Comparison of Behavioural Effects of Venlafaxine and Imipramine in Rats. Arzneimittelforschung, 2003, 53, 237-242.	0.4	17
53	Role of neuropeptides in antidepressant and memory improving effects of venlafaxine. Polish Journal of Pharmacology, 2002, 54, 605-13.	0.3	28
54	Behavioural Effects of Fluoxetine and Tianeptine, Two Antidepressants with Opposite Action Mechanisms, in Rats. Arzneimittelforschung, 2000, 50, 5-10.	0.4	36

#	Article	IF	CITATIONS
55	Some behavioural effects of risperidone in rats: comparison with haloperidol. European Neuropsychopharmacology, 1999, 9, 421-426.	0.7	20
56	An Anxiolytic-Like Effect of Ondansetron Disappears in Oxazepam-Tolerant Rats. Pharmacology Biochemistry and Behavior, 1998, 59, 935-938.	2.9	9